



Q1 2021 SALES

Investor call

April 20th, 2021

Juergen Esser, CFO

Disclaimer

- This presentation contains certain forward-looking statements concerning Danone. In some cases, you can identify these forward-looking statements by forward-looking words, such as "estimate", "expect", "anticipate", "project", "plan", "intend", "objective", "believe", "forecast", "guidance", "outlook", "foresee", "likely", "may", "should", "goal", "target", "might", "will", "could", "predict", "continue", "convinced" and "confident," the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.
- Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a description of these risks and uncertainties, please refer to the "Risk Factor" section of Danone's Universal Registration Document (the current version of which is available on www.danone.com).
- Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.
- All references in this presentation to Like-for-like (LFL) changes, recurring operating income, recurring operating margin, recurring net income, recurring income tax, recurring EPS and free cash flow correspond to financial indicators not defined in IFRS. Please refer to the financial press releases issued by the Company for further details on IAS29 (Financial reporting in hyperinflationary economies), the definitions and reconciliation with financial statements of financial indicators not defined in IFRS. Finally, the calculation of ROIC and Net Debt/Ebitda is detailed in the annual registration document.
- Due to rounding, the sum of values presented in this presentation may differ from totals as reported. Such differences are not material.

Q1 2021 Key highlights – Business delivery

Q1 2021 AT -3.3% LIKE-FOR-LIKE VS LY – LAST QUARTER OF DECLINE

- Lapping of exceptional Q1 2020 panic buying and pantry loading in Europe, North America and China
- Last quarter of full negative effects related to Covid on Danone baseline


CONFIRMED AREAS OF STRENGTH ACROSS THE PORTFOLIO

- Sustained performance momentum in developed markets for EDP, especially on the Plant-based, Probiotics and Protein platforms, but also in Indulgence
- Accelerated growth in Adult and Medical Nutrition portfolio while Infant Nutrition still impacted by China cross-border
- Sequential and gradual improvement in Waters driven by Europe

Q1 2021 Key highlights – Local First implementation progressing

Successful execution in North America: Transform to Win Key milestones achieved in Europe Continued focus on business delivery

Q1 2021 sales bridge LFL sales decline -3.3%; reported sales significantly impacted by adverse FX



Specialized Nutrition Strength in Adult; Infant Nutrition still impacted on China cross-border channels



Q1 developments

Adult Nutrition

- Continued growth led by China
- Acceleration on Healthy ageing: Fortifit & Protinex geographic expansion

Infant Nutrition

- China: steep double-digit decline driven by a -45% decline of crossborder channels while Domestic channels confirmed growth momentum
- Europe: resilient market share performance amid continued soft category dynamics
- Rest of the World: continued solid performance and share gains led by South-East Asia and Middle East

Specialized Nutrition Leveraging portfolio breadth and innovation to win on infant milks













Journey extension Cereals







Specialized Nutrition Two new Nutrilon innovations launching soon, with exclusive route-to-markets



Essential Dairy & Plant-based

Sustained performance momentum driven by Europe and North America



Q1 developments

Solid growth in Europe and North America

- Driven by Plant-based, Probiotics and Protein, but also Indulgence
- Largest sales quarter ever in North America despite high base of comparison; broad multi-category growth
- Broad-based market share gains in Europe led by Alpro, Actimel, YoPro and Danette


Flat quarter in Rest of the world

• Soft CIS dynamics, first signs of improvement in Latam and Africa

Double-digit growth in Plant-based despite high base of comparison

Essential Dairy & Plant-based

Europe: accelerating on priority platforms – Probiotics, Protein and Indulgence



Essential Dairy & Plant-based Europe: accelerating on priority platforms – Plant-based









Essential Dairy & Plant-based


North America: strong progress on both winning and acceleration platforms





Essential Dairy & Plant-based

North America: strong progress on both winning and acceleration platforms



Profitable Premium Dairy leadership



Profitable brand stretch **Revenue Growth** Management & Portfolio occasion expansion



Waters Sequential and gradual improvement; mobility still below pre-covid levels



Q1 developments

Sequential and gradual improvement; mobility still below pre-covid levels

Mobility restrictions still impacting away from home consumption

Europe gradually improving to high single-digit decline

 Continued resilience of at home formats and market share strengthin key markets (France, Germany, Poland)

China: Mizone back to growth, in line with Q4 20, still on a small quarter

Indonesia and Latin America still declining steep double-digit

Waters Focusing on core and adjacencies while exploring new models

Core acceleration







Adjacent innovation




New models





Entering the local returnable glass segment Germany

Continued progress On Danone's responsible value creation agenda



2021 Outlook 2 phase year, return to profitable growth as of H2



Despite short-term uncertainties, gradual reopening of economies assumed starting from H2, driven by progressive roll-out of vaccination programs Broad-based acceleration of inflation on milk, ingredients, packaging and logistics

Danone guidance Back to like-for-like growth as of Q2

Back to profitable growth in H2

FY recurring operating margin expected broadly in line with 2020






Q1 2021 SALES

Appendix

Q1 2021 sales by reporting entity – breakdown volume/value



Q1 2021 sales by reporting entity and by geographical area

	Essential Dairy & Plant-based	Specialized Nutrition	Waters	Company
Europe and Noram Sales LFL growth	€2,217m +2.2%	€709m -12.1%	€347m -11.6%	€3,273m -2.8%
Rest of the world Sales LFL growth	€932m +0.1%	€1,009m -4.3%	€442m -11.5%	€2,384m -4.2%
Company Sales LFL growth	€3,149m +1.6%	€1,719m -7.7%	€790m -11.6%	€5,657m -3.3%

Q1 2021 impact of currencies & scope

Q1 2021	Essential Dairy & Plant-based	Specialized Nutrition	Waters	Total
Reported sales growth	-6.4%	-11.8%	-14.9%	-9.4%
Contribution to growth from hyperinflation geographies ⁽¹⁾	+0.3%	+0.3%	+0.6%	+0.4%
Currency and others ⁽²⁾	-8.4%	-4.6%	-6.4%	-6.8%
IAS 29 impact	+0.1%	+0.1%	+0.1%	+0.1%
Scope	-	+0.1%	+2.3%	+0.4%
Like-for-like sales growth	+1.6%	-7.7%	-11.6%	-3.3%

(1) Includes IAS 29 and contribution to growth from hyperinflation geographies(2) Excluding IAS29 impact

Changes in exchange rates

	% total Q1 2021	Q1 21 vs Q1 20 (avg)
United States Dollar	22.2%	-8.5%
*: Chinese Renminbi	6.2%	-1.4%
Indonesian Rupiah	6.1%	-8.1%
Russian Ruble	5.7%	-17.4%
British Pound	5.3%	-1.3%
Mexican Peso	3.8%	-10.1%
Polish Zloty	2.6%	-4.9%
🐟 Brazilian Real	2.5%	-25.5%
C* Turkish Lira	1.9%	-24.4%
Argentine Peso	1.7%	-36.6%
Australian Dollar	1.5%	+7.7%
Japanese Yen	1.4%	-6.1%
Hong Kong Dollar	1.2%	-8.3%